MP1032 Treatment in Patients With Moderate to Severe COVID-19

Summary

The purpose of this study is to evaluate the efficacy and safety of MP1032 with standard of care (SoC) verses placebo with SoC in hospitalized adults participants with moderate to severe coronavirus disease 2019 (COVID-19).

Timeline

Start

2021-10-19

Primary completion

2022-07-28

Completion

2022-09-05

Outcome

Missed primary endpoint

registry analysis (superiority test); MP1032 300mg + SoC vs Placebo + SoC; p = 0.962; Common risk difference -0.276 (95% CI -11.634 to 11.081); Mantel Haenszel NCT04932941 ↗

Drugs

Indications